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Small Fish, Big Science
Jane Bradbury
F
rancis Hamilton, the Briton 
who ﬁ  rst described zebraﬁ  sh 
(Danio rerio) in 1822, would be 
astounded to see the scientiﬁ  c attention 
now afforded to this two-inch-long 
native of Indian rivers. A ﬁ  sh with no 
economic worth was how he described 
this little creature. Yet recently, the 
European Union awarded 12 million 
Euros to the ZF-MODELS research 
consortium to study zebraﬁ  sh models 
for human development and disease. 
When and why did zebraﬁ  sh swim from 
home aquaria into research labs, and 
what can we learn about our biology 
from this surprising source?
The Early Days
It was the late 1960s when phage 
geneticist George Streisinger began 
to look for a model system in which to 
study the genetic basis of vertebrate 
neural development. His passion for 
tropical ﬁ  sh led him to the humble 
zebraﬁ  sh. He was a ‘visionary’, 
remembers neurobiologist Judith 
Eisen (University of Oregon, Eugene, 
Oregon, United States), ‘who laid the 
groundwork for the use of zebraﬁ  sh as 
a developmental model’.
Eisen, who now heads her own 
research group, went to Oregon 
in 1983 to work on Xenopus neural 
development but soon became 
attracted to zebraﬁ  sh as a model 
organism. By the early 1980s, she 
explains, Streisinger had worked out 
many of the genetic tricks needed 
to tackle zebraﬁ  sh development. 
What’s more, the ﬁ  sh had ‘wonderful 
embryology’. The embryo, which 
develops outside its mother, is 
transparent. ‘You can see different cell 
types, watch individual cells develop, 
do transplantation experiments’, 
Eisen enthuses, ‘and development is 
quick but not too quick’. Being able to 
watch individual neurons developing 
in real time opened up whole new 
avenues of research for Eisen and other 
neurobiologists.
Fast Forward to the Big Screen 
The properties of zebraﬁ  sh that 
attracted Eisen soon attracted people 
interested in other aspects of vertebrate 
development to the stripy tiddler 
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(Figure 1). As Eisen comments: ‘No 
other developmental model has risen 
to prominence so quickly’. These 
days more than 3,000 researchers are 
listed on ZFIN, a United States–based 
information resource for the zebraﬁ  sh 
research community.
The speedy expansion was driven 
in great part by two genetic screens 
initiated in 1992  –1993 by Christiane 
Nüsslein-Volhard in Tübingen, 
Germany, and Wolfgang Driever 
and Mark Fishman in Boston, 
Massachusetts. The aim of both screens 
was to identify genes with unique 
and essential functions in zebraﬁ  sh 
development, and in 1996 an issue of 
the journal Development was dedicated 
to the mutants that had been isolated 
and characterised. These screens, says 
Ralf Dahm (Max Planck Institute for 
Developmental Biology, Tübingen, 
Germany), project manager of the 
ZF-MODELS consortium, ‘were the 
ﬁ  rst major zebraﬁ  sh projects, and they 
showed that zebraﬁ  sh was a model 
organism to be reckoned with’.
‘That was a fantastic time’, says 
Derek Stemple, then a postdoc with 
Driever but now a group leader at 
the Wellcome Trust Sanger Institute 
(Cambridge, United Kingdom) and 
a ZF-MODELS participant. ‘From 
Wolfgang’s lab, I was able to take the 
mutations that affected notochord 
development, and have been studying 
them ever since’. The notochord is 
an embryonic structure that forms 
the primitive axial skeleton of the 
developing embryo, and because 
mutations affecting notochord 
development result in shortened 
embryos, seven of the affected genes 
have been named after the dwarves 
in Snow White—zebraﬁ  sh, like some 
other developmental models, have 
many imaginatively named mutants. 
Stemple now knows the identity of 
six of these mutated genes, all of 
which lead to disruption of basement 
membrane around the notochord. 
Many mutants from those ﬁ  rst two 
screens are still used by developmental 
biologists, but another set of 
mutants has recently been isolated 
by Nancy Hopkins, Amgen Professor 
of Biology at the Massachusetts 
Institute of Technology (Cambridge, 
Massachusetts, United States). About 
ten years ago, Hopkins started to 
develop insertional mutagenesis in 
zebraﬁ  sh (Figure 2). In this approach, 
mutations are caused by the random 
insertion of viral DNA throughout the 
ﬁ  sh genome. The inserted DNA acts 
as a tag, making cloning of mutated 
genes very straightforward, although 
the efﬁ  ciency of the initial insertional 
mutagenesis is much lower than that 
of the chemical mutagenesis used in 
the 1992–1993 screens. Hopkins has 
isolated 550 mutants in her screen, 
representing around 400 different 
genes, and has cloned more than 300 
of these genes to date. Some of the 
fruits of this project are published in 
this issue of PLoS Biology. Hopkins’s 
group is now collaborating with 25 
external laboratories on the annotation 
of the mutant collection with funding 
from the National Center for Research 
Resources, part of the United States 
National Institutes of Health.
The Tübingen researchers did 
another chemical mutagenesis screen 
between 2000 and 2001, and are 
now starting a third screen of 6,000 
genomes as part of the ZF-MODELS 
project. ‘Each of our screens has built 
on the previous one by including 
more speciﬁ  c assays’, explains Dahm. 
Mutagenesis for the third screen is 
underway, but the assays, which include 
looking for defects that speciﬁ  cally 
affect adults, are still at the pilot stage; 
this autumn, the project’s executive 
committee, which is headed by 
Nüsslein-Volhard, will decide which 
assays to use in the full-scale screen. 
‘Just over half the 17 partners in the 
consortium will come to Tübingen 
to do screens’, predicts Dahm. ‘By 
bringing in expertise in different 
systems in this way we should greatly 
increase the efﬁ  ciency of the screen’. 
What Else Will ZF-MODELS Do?
The ZF-MODELS consortium, 
which is funded under the European 
Union’s Sixth Framework Programme, 
aims to establish zebraﬁ  sh models for 
human diseases, discover genes that 
will lead to the identiﬁ  cation of new 
drug targets, and gain fundamental 
insights into human development. ‘We 
will mainly focus on using advanced 
technologies that have recently become 
available’, says scientiﬁ  c coordinator 
Robert Geisler (Max Planck Institute 
for Developmental Biology). For 
example, Geisler’s lab will use DNA 
chip technology to investigate gene 
DOI: 10.1371/journal.pbio.0020148.g001
Figure 1. Adult Zebraﬁ  sh
(Image courtesy of Lukas Roth, University 
College London, London, United 
Kingdom.)
Because mutations affecting 
notochord development 
result in shortened embryos, 
seven of the affected genes 
have been named after the 
dwarves in Snow White.
DOI: 10.1371/journal.pbio.0020148.g002
Figure 2. A Zebraﬁ  sh Pigment Mutant
The mutant called bleached blond was 
produced by insertional mutagenesis. The 
embryos in the picture are four days old. 
At the top is a wild-type embryo, below 
is the mutant. The mutant lacks black 
pigment in the melanocytes because it 
fails to synthesise melanin properly. 
(Image courtesy of Adam Amsterdam, 
Massachusetts Institute of Technology, 
Boston, Massachusetts, United States.)May 2004  |  Volume 2  |  Issue 5  |  Page 0570 PLoS Biology  |  http://biology.plosjournals.org
expression patterns in zebraﬁ  sh 
mutants and so provide increased 
knowledge of the regulatory pathways 
that act in zebraﬁ  sh development.
Consortium members will also 
use ‘reverse genetics’ to investigate 
these pathways. In reverse genetics, 
researchers start with a gene of interest 
and investigate the phenotypic effect 
of altering its activity; by contrast, in 
‘forward genetics’ the starting point 
is to look for a particular phenotype 
and then hunt out the altered 
gene that is causing it. Two reverse 
genetics approaches will be used by 
the consortium. Gene expression 
will be transiently knocked down 
with morpholinos, short segments 
of the gene that block its function. 
In addition, a recently developed 
technique known as TILLING 
(targeting induced local lesions in 
genomes) will be used to knock out 
gene activity permanently. 
The ﬁ  rst step in TILLING is to 
mutagenise male zebraﬁ  sh and mate 
them with untreated female ﬁ  sh, 
explains Stemple, whose group is one 
of three ZF-MODELS partners who 
will use this approach. Offspring are 
raised to adulthood, and the DNA of 
each individual is then genotyped for 
the exon of interest. The consortium 
already has a collection of 6,000 such 
individuals, and once a ﬁ  sh carrying 
a mutation in the gene of interest has 
been identiﬁ  ed, it will be outcrossed 
to produce offspring, half of which will 
carry the desired mutation on one of 
their chromosomes. ‘It is then a matter 
of identifying these heterozygote ﬁ  sh 
and incrossing them to get homozygous 
ﬁ  sh in which you can see the phenotype 
that correlates with that mutation’, says 
Stemple.
As well as helping to produce knock-
outs for other researchers, Stemple is 
also using the TILLING technique to 
develop zebraﬁ  sh models for muscular 
dystrophy. Among the genes that are 
important in notochord development 
are those that encode laminins. This 
led Stemple into studying muscular 
dystrophy because laminins are 
involved in the human disease. ‘When 
we used morpholinos to disrupt [the 
production of] dystroglycan, a laminin 
receptor, we got a good model for 
muscular dystrophy’, he explains. 
Now, he plans to use TILLING to 
disrupt up to 30 other genes known 
to be involved in human muscular 
dystrophy. ‘In particular, we will look 
for hypomorphic mutants, ﬁ  sh that are 
viable but on the edge of falling apart’. 
These mutants can be used to identify 
small molecules that push the ﬁ  sh into 
muscular dystrophy. Finding molecules 
that can cause a disease in this way 
‘might give us a handle on something 
to ﬁ  x the disease’, says Stemple.
In another strand of the ZF-MODELS 
project, zebraﬁ  sh expressing green 
ﬂ  uorescent protein (GFP) in speciﬁ  c 
cells or tissues will be generated and 
characterised (Figure 3). In such 
ﬁ  sh, developing structures can be 
easily imaged over time in the living 
embryo. One researcher working on 
this aspect of the project is Stephen 
Wilson, Professor of Developmental 
Genetics at University College London 
(United Kingdom). GFP lines can be 
made either by attaching to the GFP 
gene regions of DNA that control, or 
‘drive’, GFP expression in selected cell 
types or by allowing the GFP gene to 
insert randomly in the genome and 
looking for ﬁ  sh with speciﬁ  c expression 
patterns. ‘There are now many lines 
of ﬁ  sh available with different GFP 
expression patterns’, says Wilson, 
‘and it is important to catalogue their 
expression so that people can use 
the most appropriate lines for their 
research’.
Wilson’s own interest is in 
neuroanatomy. Together with Jon 
Clarke, another developmental 
neurobiology group leader at 
University College London, he plans 
to analyse GFP lines in which small 
groups of neurons or particular parts 
of neurons are labelled, and in this way 
start to build a detailed reconstruction 
of early brain neuroanatomy. This, 
in combination with other work on 
zebraﬁ  sh carrying mutations affecting 
neural development, will give the team 
‘a better picture of how a vertebrate 
brain is built’.
A ﬁ  nal, important aspect of the 
ZF-MODELS project, adds Dahm, is 
database construction. ‘We will be 
developing a set of databases that 
will integrate all of the project data’, 
he explains. ‘In addition, we hope to 
integrate our data with that of ZFIN in 
the United States to make one central 
zebraﬁ  sh resource’.
But Fish Aren’t People
The researchers of the ZF-MODELS 
consortium are understandably excited 
about participating in what will, 
‘When we used morpholinos 
to disrupt dystroglycan, a 
laminin receptor, we got a 
good model for muscular 
dystrophy’.
DOI: 10.1371/journal.pbio.0020148.g003
Figure 3.  Zebraﬁ  sh Hindbrain
(Left) Dorsal view of GFP-expressing neurons in the hindbrain of a one-day-old zebraﬁ  sh 
embryo. (Right) Antibody-labelled axons. 
(Image courtesy of Dave Lyons, University College London.)May 2004  |  Volume 2  |  Issue 5  |  Page 0571 PLoS Biology  |  http://biology.plosjournals.org
says Geisler, bring an already strong 
European zebraﬁ  sh community closer 
together. But zebraﬁ  sh researchers in 
the United States are also excited by 
the ZF-MODELS project. ‘We need 
big lab models like ZF-MODELS in 
developmental biology’, says Hopkins, 
noting that the days of small groups 
working in isolation are long gone. 
This consortium, adds Howard Hughes 
Medical Institute Investigator Leonard 
Zon (Harvard Medical School, Boston, 
Massachusetts, United States), ‘will 
not only have an effect on European 
zebraﬁ  sh science but also on how it is 
done in the United States’. 
But how much can zebraﬁ  sh 
tell us about human development 
and disease? A lot, say zebraﬁ  sh 
researchers. ‘Fish really are just little 
people with ﬁ  ns’, says Hopkins. ‘Of 
course, there are developmental 
differences between people and 
ﬁ  sh, and no one pretends that we 
can answer every question about 
human development in zebraﬁ  sh’. 
Nevertheless, zebraﬁ  sh studies can 
provide valuable clues to the genes 
involved in human diseases and to 
potential targets for therapeutic 
interventions. Hopkins provides the 
following illustration: ‘We have been 
doing “shelf screens”, in which we 
go back to our collection of mutants 
to ﬁ  nd all those that affect the 
development of a single organ. When 
Zhaoxia Sun, a postdoc in my lab who 
now has an independent position 
at Yale Medical School, screened 
three-day-old ﬁ  sh for cystic kidney 
disease, she found 12 different genes. 
Two were known to cause human 
cystic kidney disease, so we knew we 
were in the human disease pathway 
somewhere, but we had no idea 
what the other genes were’. Hopkins 
and Sun have since identiﬁ  ed the 
remaining genes, and these point to a 
single pathway being involved in the 
human disease. 
Developmental geneticist Didier 
Stainier (University of California, San 
Francisco, California, United States) 
is also using zebraﬁ  sh to study organ 
development, in particular, heart 
development. The zebraﬁ  sh heart is 
like the early human heart—a tube 
with an atrium, ventricle, and valves. 
‘Everything we have found in the 
ﬁ  sh is relevant to the human heart’, 
says Stainier. ‘Obviously, there are 
additional processes involved in 
humans, but the basic outline of heart 
development in ﬁ  sh and people is 
largely similar’. Stainier has a collection 
of zebraﬁ  sh in which valve formation 
is faulty. ‘Some of the genes we have 
found will be involved in human 
congenital valve defects’, he predicts. 
Knowing the identity of these genes 
will be useful diagnostically, but, in 
addition, zebraﬁ  sh studies can reveal 
exactly what has gone wrong at a 
cellular level. The ability to follow 
individual cells as organs develop is 
key to this, says Stainier, who reported 
in March that ﬁ  bronectin is required 
for heart development because, by 
regulating the polarisation of epithelial 
cells, ﬁ  bronectin ensures the correct 
migration of myocardial cells. And in 
this issue of PLoS Biology, Stainier’s lab 
have identiﬁ  ed another zebraﬁ  sh gene 
that is involved in heart development—
cardiofunk, which encodes a special 
type of muscle protein.
A Proliferation of Zebraﬁ  sh Models 
of Human Disease
Many researchers are now 
recognising the value of zebraﬁ  sh 
models of human disease. Over the 
past three to four years, says Zon, this 
area of research has become a growth 
industry. The interest in disease models 
has grown hand-in-hand with the 
development of morpholinos to knock 
out speciﬁ  c genes, and the advent of 
TILLING, says Zon, ‘has set off a whole 
new fury. There are now large numbers 
of investigators who will try to knock 
out their favourite gene and come up 
with a model’.
Zon has worked on disease models 
for blood (Figure 4), blood vessel, and 
heart disorders but is currently studying 
zebraﬁ  sh models of cancer. ‘We started 
by doing chemical mutagenesis and 
screened for cell-cycle mutants. These 
were embryonic lethals, but when we 
looked at heterozygote carriers of these 
mutations, some developed cancer at 
a high rate as adults’. Now Zon and his 
colleagues have returned to the cell-
cycle mutant that yielded this cancer-
susceptible heterozygote and are using 
embryos in high-throughput screening 
assays to look for small molecules that 
can suppress the cell-cycle phenotype. 
These molecules, reasons Zon, may 
have potential as anticancer drugs. 
And the Future of Zebraﬁ  sh 
Research?
Bigger and bigger seems to be 
the consensus. Chemical screens 
like Zon’s for anticancer drugs can 
be set up for other human diseases 
such as muscular dystrophy. Work 
like Stainier’s on organ development 
may have applications in tissue 
engineering. ‘If we can ﬁ  nd out what 
drives differentiation in zebraﬁ  sh’, he 
suggests, ‘we might be able to do the 
same for human cells’, making human 
‘Fish really are just little 
people with ﬁ  ns’.
DOI: 10.1371/journal.pbio.0020148.g004
Figure 4.  Zebraﬁ  sh kugelig Mutants
The image shows live one-week-old 
zebraﬁ  sh embryos. The embryos around 
the outside are wild-type ﬁ  sh. Those in 
the middle are a mutant called kugelig 
and have a homozygous mutation in 
a gene called cdx4. Loss of the proper 
functioning of this gene causes the 
obvious trunk and tail defects but also 
causes a reduction in the number 
of haematopoietic stem cells in the 
embryos, which therefore become 
severely anaemic. Studies on this mutant 
might lead to the discovery of molecules 
that can drive stem cell differentiation, 
for example, or could help improve 
understanding of human haematological 
malignancies. 
(Image courtesy of Alan Davidson, 
Harvard Medical School, Boston, 
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tissue replacement therapy a practical 
possibility. And while many zebraﬁ  sh 
researchers will continue to study 
development, others are now moving 
into the realms of physiology and 
behavioural studies.
Geisler sums up zebraﬁ  sh 
developmental research past, present, 
and future as follows: ‘No other 
[vertebrate] organism offers the 
same combination of transparent 
and accessible embryos, cost-effective 
mutagenesis screening, and, more 
recently, a sequenced genome, [DNA] 
chip, GFP, and knockout technology’. 
Add to that the potential of zebraﬁ  sh 
embryos as a screening platform for 
small molecule libraries and the new 
technologies that allow forward and 
reverse genetics, and it is clear that 
zebraﬁ  sh are not about to revert to 
being pretty pets swimming in small 
tanks in the corner of the living room.  
Where to Find Out More
ZF-MODELS
More details of the work included in this European 
Union Integrated Project can be found at 
http:⁄⁄www.zf-models.org.
ZFIN
The ZFIN Web site, at http:⁄⁄zﬁ  n.org/ZFIN, 
provides an extensive database for the zebraﬁ  sh 
community including genetic, genomic, and 
developmental information; search engines for 
zebraﬁ  sh researchers and laboratories; listings 
of meetings; and links to many other zebraﬁ  sh 
sites, including sites with movies of zebraﬁ  sh 
development.
The special issue of Development (Dec 1; 1996; 123: 
1–461) on the ﬁ  rst two mutagenesis screens 
contains 37 research articles and can be freely 
accessed at http:⁄⁄dev.biologists.org/content/
vol123/issue1/index.shtml.
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